Reagents and methods for detecting influenza virus proteins

Details Reagents and methods for detecting influenza virus proteins Reagents and methods for detecting influenza virus proteins

A - Human Necessities

61

K

A61K 39/385 (2006.01) A61K 39/145 (2006.01) A61P 31/16 (2006.01) A61P 37/04 (2006.01) C07K 16/10 (2006.01) C07K 16/40 (2006.01) C12N 9/24 (2006.01) C12N 11/02 (2006.01) C12P 21/08 (2006.01) G01N 33/15 (2006.01) G01N 33/573 (2006.01)

Patent

CA 2761733

Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.

Selon l'invention, deux séquences de neuraminidases de la grippe de type A universellement conservées ont été identifiées par analyse séquentielle à grande échelle puis modifiées chimiquement et conjuguées avec des protéines support pour générer des anticorps mono-spécifiques et monoclonaux. Les deux anticorps, l'un ciblant le N-terminus de la neurominidase de type A et l'autre la séquence à proximité du site enzymatique actif, peuvent se lier aux 9 sous-types de neurominidase tout en démontrant une spécificité remarquable contre les séquences de neurominidase virales puisqu'aucune réactivité croisée contre des protéines allantoïques n'a été observée. Des analyses quantitatives de NA utilisant la technique «slot-blot» suggèrent que les anticorps peuvent servir pour la quantification d'antigènes NA dans les vaccins. Il est donc démontré que c'est la première fois que le dosage à base d'anticorps peut être utilisé pour la détermination quantitative de NA.

Affiliated with

Also associated with

Rating

Reagents and methods for detecting influenza virus proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reagents and methods for detecting influenza virus proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reagents and methods for detecting influenza virus proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1704997